Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 15/20 | 0.80 |
| ▸ | PDGFRA | P16234 | 12/20 | 0.80 |
| ▸ | BCR | P11274 | 9/20 | 0.80 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.80 |
| ▸ | EGFR | P00533 | 1/20 | 0.73 |
| ▸ | PRKCA | P17252 | 1/20 | 0.73 |
| ▸ | KIT | P10721 | 6/20 | 0.71 |
| ▸ | LCK | P06239 | 1/20 | 0.71 |
| ▸ | LYN | P07948 | 1/20 | 0.71 |
| ▸ | FLT3 | P36888 | 1/20 | 0.71 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.71 |
| ▸ | KDR | P35968 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1656154 | 0.91 | PDGFRA (0.90) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL1654172 | 0.91 | PDGFRA (0.79) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL1654378 | 0.90 | ABL1 (0.82) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL9677 | 0.89 | PDGFRA (1.00) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL24532067 | 0.88 | ABL1 (0.62) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL1927376 | 0.88 | PDGFRA (0.79) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL1653493 | 0.88 | ABL1 (0.77) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL1655072 | 0.87 | ABL1 (0.81) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL1654099 | 0.87 | ABL1 (0.74) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL3973176 | 0.86 | ABL1 (0.82) | ABL1PDGFRABCRPDGFRBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2368889-A1 | Inhibitors of tyrosine kinases | Novartis AG (CH) | 2011-09-28 | — | — | EP | disclosed |
| US-20110218187-A1 | INHIBITORS OF TYROSINE KINASES | BREITENSTEIN WERNER | 2011-09-08 | — | — | US | disclosed |
| EP-2357182-A1 | Inhibitors of tyrosine kinases | Novartis AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-7956053-B2 | Inhibitors of tyrosine kinases | NOVARTIS AG (CH) | 2011-06-07 | — | — | US | disclosed |
| US-20090286821-A1 | INHIBITORS OF TYROSINE KINASES | BREITENSTEIN WERNER | 2009-11-19 | — | — | US | disclosed |
| EP-2100891-A1 | Inhibitors of tyrosine kinases | Novartis AG (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-7569566-B2 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | NOVARTIS AG (CH) | 2009-08-04 | — | — | US | disclosed |
| US-20080188451-A1 | INHIBITORS OF TYROSINE KINASES | BREITENSTEIN WERNER | 2008-08-07 | — | — | US | disclosed |
| CN-101045727-A | Inhibitors of tyrosine kinases | NOVARTIS AG (CH) | 2007-10-03 | — | — | CN | disclosed |
| CN-1324022-C | Tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2007-07-04 | — | — | CN | disclosed |
| US-20070093506-A1 | Inhibitors of tyrosine kinases | BREITENSTEIN WERNER | 2007-04-26 | — | — | US | disclosed |
| US-7169791-B2 | Inhibitors of tyrosine kinases | NOVARTIS AG (CH) | 2007-01-30 | — | — | US | disclosed |
| US-20060167015-A1 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
| CN-1675195-A | Tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2005-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093506-A1 | Inhibitors of tyrosine kinases | ABL1, BTK, FLT3 | ABL1 1/4885PDGFRA 382/4885BCR 28/4885 |
| US-20110218187-A1 | INHIBITORS OF TYROSINE KINASES | ABL1, BTK, FLT3 | ABL1 1/4885PDGFRA 382/4885BCR 28/4885 |
| US-20080188451-A1 | INHIBITORS OF TYROSINE KINASES | ABL1, BTK, FLT3 | ABL1 1/4885PDGFRA 382/4885BCR 28/4885 |
| US-20090286821-A1 | INHIBITORS OF TYROSINE KINASES | ABL1, BTK, FLT3 | ABL1 1/4885PDGFRA 382/4885BCR 28/4885 |
| US-20060167015-A1 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | ABL1, CDK2, CDKN1A | ABL1 1/4885PDGFRA 440/4885BCR 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.